KLHL32 Antibody

Introduction to KLHL32 Antibody

KLHL32 antibodies are immunological tools designed to detect and study the Kelch-like protein 32 (KLHL32), a member of the Kelch-like (KLHL) family. These antibodies are critical for investigating KLHL32’s roles in cellular processes, including ubiquitination, protein degradation, and potential involvement in disease pathways. KLHL32, encoded by the KLHL32 gene (Entrez ID: 114792), is characterized by its BTB-Kelch domain structure, which facilitates interactions with substrates and components of the ubiquitin-proteasome system .

Role in Disease and Research Findings

While KLHL32’s exact biological functions remain under investigation, its homology to other KLHL family members suggests roles in:

• Ubiquitination: KLHL proteins form E3 ubiquitin ligase complexes with Cullin3, tagging substrates for proteasomal degradation .

• Cancer: Limited studies associate KLHL32 with tumorigenesis. For example, KLHL38 (a related family member) degrades PTEN to activate oncogenic PI3K/AKT signaling in lung cancer . KLHL32’s expression in cancers like glioblastoma and NSCLC is documented, though mechanistic insights are sparse .

Table 1: KLHL32 Expression in Human Tissues

Reagent Development and Validation

KLHL32 antibodies are commercially available with diverse validation data:

Table 2: Key Antibody Reagents

Clinical and Therapeutic Implications

• Neurological Disorders: While KLHL11 antibodies are linked to paraneoplastic encephalitis , KLHL32-specific clinical associations are not yet established.

• Cancer Research: KLHL32’s interaction with substrates like NF-κB or Aurora kinases (inferred from KLHL family studies) may influence chemotherapy sensitivity or tumor progression .

Challenges and Future Directions

• Functional Elucidation: KLHL32’s substrate specificity and degradation mechanisms require further study.

• Therapeutic Potential: Targeting KLHL32-associated pathways (e.g., ubiquitination) could offer novel strategies for cancer or neurodegenerative diseases .